Loyal’s longevity drug for large dogs advances after FDA efficacy approval

Loyal’s LOY-003 tablet has cleared the efficacy review section of its US veterinary approval filing, giving the company efficacy acceptance across all three of its canine longevity programmes. The milestone advances its efforts to develop medicines aimed at extending healthy lifespan in dogs.

Loyal said its LOY-003 tablet has cleared the efficacy review section of its US veterinary approval filing, taking the company another step towards a proposed drug for extending the lifespan of large dogs. The milestone matters because it leaves the animal health group with efficacy acceptances across its entire longevity portfolio, although any commercial launch still depends on remaining regulatory hurdles. For a sector long focused on treating age-related disease rather than ageing itself, the result underscores both the scientific ambition and the regulatory uncertainty surrounding lifespan-extending medicines.

The San Francisco-based company said the FDA has completed the Reasonable Expectation of Effectiveness review for LOY-003, its candidate for large and giant breeds. Loyal said that gives it efficacy acceptance across all three of its longevity programmes.

The firm has built its pipeline around interventions aimed at biological mechanisms associated with ageing, including insulin resistance in older dogs and hormone pathways linked to rapid growth in large breeds. Its lead programme, LOY-002, has already cleared both efficacy and safety sections and is now in a pivotal field study.

Loyal says it is the only company working with the FDA on lifespan extension as a potential indication. The company, which says it has raised more than $250m, is seeking to make LOY-002 the first drug approved for canine lifespan extension.